Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CDK4 Antibodies:
anti-Mouse (Murine) CDK4 Antibodies:
anti-Rat (Rattus) CDK4 Antibodies:
Go to our pre-filtered search.
Human Polyclonal CDK4 Primary Antibody for IHC (p), WB - ABIN3043745
Li, Xu, Chu, Gao, Wang, Nie, Yang, Lv: Molecular mechanism of inhibitory effects of CD59 gene on atherosclerosis in ApoE (-/-) mice. in Immunology letters 2013
Show all 9 Pubmed References
Human Monoclonal CDK4 Primary Antibody for ICC, WB - ABIN3043633
Ren, Huang, Xu, Yang, Yang, Hu: Isoflavone lupiwighteone induces cytotoxic, apoptotic, and antiangiogenic activities in DU-145 prostate cancer cells. in Anti-cancer drugs 2015
Show all 9 Pubmed References
Human Polyclonal CDK4 Primary Antibody for WB - ABIN3042691
Zhou, Lu, Liu, Guo, Liu, Zhou, Yang, Mi, Xu: Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo. in Current cancer drug targets 2015
Show all 9 Pubmed References
Human Polyclonal CDK4 Primary Antibody for FACS, IF - ABIN391751
Mori, Yang, Kawamata, Miller, Mizoguchi, Koeffler: Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors. in International journal of hematology 2003
Show all 5 Pubmed References
Human Polyclonal CDK4 Primary Antibody for IF (p), IHC (p) - ABIN671166
Zhou, Liu, Cai, Liu, Jiang, Wang: Protective effects of ginsenoside Rg1 on aging Sca?1+ hematopoietic cells. in Molecular medicine reports 2015
Show all 2 Pubmed References
Human Polyclonal CDK4 Primary Antibody for ELISA, IHC - ABIN6266370
Wang, Ge, Zhang, Chen, Hu, Li, Ye: Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis. in Journal of experimental & clinical cancer research : CR 2016
Show all 2 Pubmed References
Human Monoclonal CDK4 Primary Antibody for ICC, IF - ABIN267545
Brookes, Gagrica, Sanij, Rowe, Gregory, Hara, Peters: Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence. in Cell cycle (Georgetown, Tex.) 2015
Human Polyclonal CDK4 Primary Antibody for ELISA, WB - ABIN6267732
Wu, Herman, Brock, Wu, Mao, Yan, Nie, Liang, Zhan, Li, Guo: Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling. in PLoS ONE 2015
Cow (Bovine) Polyclonal CDK4 Primary Antibody for ICC, IF - ABIN441316
Huang, Kao, Toh, Lin, Chou, Hu, Lu, Liou, Chao, Hour, Pu: UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity. in Biochemical pharmacology 2011
Rat (Rattus) Polyclonal CDK4 Primary Antibody for WB - ABIN1881714
Cho, Phillips, Khan, Weaver: Cloning of the rat cyclin-dependent kinase 4 cDNA: implication in proliferation-dependent expression in rat tissues. in Biochemical and biophysical research communications 1993
Expression of cells a mutant CDK4 (CDK4(R24C)) in beta-cells enhanced beta-cell replication. CDK4(R24C) also dampened compensatory beta-cell neogenesis in larvae and improved glucose tolerance in adult zebrafish.
MiR (show MLXIP Antibodies)-340 overexpression inhibited tumor growth by regulating CDK4 expression. miR (show MLXIP Antibodies)-340 functions as a tumor suppressor in non small cell lung cancer (NSCLC) cells and may provide a potential target of NSCLC treatment.
CDK4 and XPO1 (show XPO1 Antibodies) are not altered in a rare undifferentiated sarcoma, making them therapeutic targets
while mTOR (show FRAP1 Antibodies) inhibitors restore endocrine sensitivity, CDK4/6 inhibitors may favor the emergence of estrogen receptor 1 (ESR1 (show ESR1 Antibodies)) mutations resulting in ligand-independent activity of the receptor
Inhibition of CDK4/6 is potentially a highly effective strategy for the treatment of SHH (show SHH Antibodies) and MYC (show MYC Antibodies)-amplified group 3 medulloblastoma.
SOX12 (show SOX12 Antibodies) can increase the expression of CDK4 and IGF2BP1 (show IGF2BP1 Antibodies), which confer malignant phenotypes to Hepatocellular Carcinoma.
Study showed that CDK4 and BCAS2 (show BCAS2 Antibodies) may be target genes of miR (show MLXIP Antibodies)-486 and levels of CDK4 and BCAS2 (show BCAS2 Antibodies) were both significantly higher in the esophageal cancer tissues and cell lines than levels in the normal tissues and cells.
Results suggest that dysregulation and activation of the cell cycle proteins CDK4/CDK6 (show CDK6 Antibodies)-CCND1 (show CCND1 Antibodies)-phospho-RB1 (show RB1 Antibodies) axis is associated with higher proliferative index in neuroendocrine tumors (NETs).
blocking CDK4 activity efficiently eliminated both normal and chemotherapy-resistant cancer cells in triple negative breast cancers, highlighting CDK4 as a promising novel therapeutic target for these aggressive breast tumors.
Amplification of gene CDK4 is associated with lung adenocarcinoma.
PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation
The in vitro cultivation of cumulus cells was associated with cell proliferation and that Cx43 (show GJA1 Antibodies) and Cdk4 gene expression was upregulated after in vitro cultivation, resulting in significantly higher protein levels.
These results indicate that p18 (show CDKN2C Antibodies) blocks reprogramming by targeting Cdk4/6-mediated cell cycle regulation.
Activation of cdk4 triggers NAFLD (show TSC2 Antibodies).
This novel mechanism explains how CDK4 promotes anabolism by blocking catabolic processes (FAO) that are activated by AMPK (show PRKAA1 Antibodies).
PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration.
The results demonstrate a unique CDK4-mediated mitochondrial communication that allows cells to sense environmental genotoxic stress and boost mitochondrial homeostasis by enhancing phosphorylation and activation of MnSOD (show SOD2 Antibodies).
a crucial role of RXRa in suppression of UVB-induced melanomas in the context of driver mutations such as activated CDK4(R24C/R24C) or oncogenic NRAS(Q61K) and altered expression of p53 and PTEN
Our data indicate that Cdk2 (show CDK2 Antibodies) and Cdk4 play important overlapping roles in homeostatic and stress hematopoiesis, which need to be considered when using broad-spectrum cyclin-dependent kinase (show CDK1 Antibodies) inhibitors for cancer therapy.
CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 (show CDK2 Antibodies) is dispensable for tumorigenesis in these neuroendocrine cell types.
Cdk4 and Cdk6 (show CDK6 Antibodies) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (show CDK6 Antibodies) in sequestering INK4 proteins away from Cdk4.
CCND1 mRNA expression is increased by FGF9 in bovine theca cells and granulosa cells.
The results indicate that the precise regulation of neuronal Cdk4 activity is important to limit mitochondrial reactive oxygen species production and prevent neurodegeneration.
CDK4 activity regulates mitobiogenesis by the activation of NRF-1 (show NRF1 Antibodies) and consequent induction of Tfam (show TFAM Antibodies) and mitochondrial ribossomal transcription.
Delg and cyclin D/Cdk4 have roles in nutritional control of mitochondrial biogenesis in the Drosophila adipose tissue
Cyclin D-cdk4 is not a master regulator of cell multiplication in Drosophila embryos
mRpL12 (show MRPL12 Antibodies) is required for CycD/Cdk4-induced cell growth
Our data suggest that the growth-specific function of CycD/Cdk4 is conserved from arthropods to mammals.
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported.
cell division protein kinase 4
, cyclin dependent kinase 4
, serine/threonine kinase
, Cell division protein kinase 4
, Cyclin-dependent kinase 4/6
, cyclin-dependent kinase 4
, protein kinase-like 53C